The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors Abstract #1689

Introduction: The expression of cytokeratins (CK) 7,19 rarely occurs in the low grade neuroendocrine tumors (NET) of lung and pancreas. It is known that part of the low grade typical (TC) and atypical (ATС) carcinoids of lung and pancreas (pNET-G1,G2) can progress quickly and to metastasize. It is important to distinguish NET with a less differentiated cells immunophentype.
Aim(s): To examine of the expression of CK 7 and 19 in NET.
Materials and methods: The expression of CK7 and 19 was examined by immunohistochemistry method in to 339 NET: 49 TC, 32 ATC, 60 small-cell (SCC), 11 large cell neuroendocrine carcinomas of the lung (LCC); 78, 98 pNET-G1 and G2 (respectively), 11 pNEC-G3.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Iya A Voronkova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#239 CK 19 Expression in Pancreatic Neuroendocrine Tumors as Negative Prognostic Factor and a Risk Factor for Metastases
Introduction: Neuroendocrine tumors (NET) of the pancreas are slow growing neoplasms, but they can metastasize after many years after surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larisa Gurevich
#417 CK19 Expression in A?TH-Producing Extrapituitary Neuroendocrine Neoplasms is a Negative Prognostic Factor
Introduction: Defining localization and potential ?CTH-producing extrapituitary neuroendocrine neoplasms (ACTH-epNEN) is important for clinical practice.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: I Voronkova
#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich
#1279 Epidemiology Survival and Prognosis of Neuroendocrine Tumors: A Multidisciplinary Single-Center Study
Introduction: There is no certain consensus about prognostic factors of NETs.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ersin Özaslan
#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: Oxaliplatin, NETs